CJC-1295 vs Sermorelin: GHRH Analogues in Research
- ✓Both CJC-1295 and sermorelin target the GHRH receptor (GHRHR) in pituitary somatotrophs — but with radically different half-lives: sermorelin ~7-11 minutes vs CJC-1295 DAC ~6-8 days
- ✓Sermorelin produces acute, pulsatile GH stimulation — preserving normal somatostatin feedback. CJC-1295 DAC produces sustained GH elevation across days, blunting pulsatile patterns
- ✓Sermorelin has FDA approval history (Geref) for GH deficiency — providing Phase 3 clinical data unusually rare for a research peptide
- ✓CJC-1295 Phase 2 data (Teichman et al., J Clin Endocrinol Metab 2006) confirmed sustained GH/IGF-1 elevation lasting 6 days from a single administration
- ✓Both available wholesale in Australia from Eternal Peptides Wholesale — Janoshik COA-verified, for qualified laboratory research use only
In This Article
GHRH Analogues: The Same Target, Different Pharmacokinetics
CJC-1295 and sermorelin both act on the growth hormone-releasing hormone receptor (GHRHR) in pituitary somatotrophs, stimulating GH synthesis and pulsatile release. However, their pharmacokinetic profiles are radically different — and that difference defines the research designs for which each is suitable. Choosing between them is primarily a question of study duration and GH pulse dynamics rather than mechanism.
Sermorelin: Short-Acting GHRH Reference Compound
Sermorelin (GHRH 1-29) is a synthetic 29-amino acid peptide corresponding to the N-terminal fragment of native GHRH. This fragment retains full GHRHR binding activity — native GHRH is 44 amino acids but the 1-29 sequence contains the receptor-binding domain responsible for all documented biological activity.
Sermorelin's plasma half-life is approximately 7-11 minutes — determined by rapid DPP-IV (dipeptidyl peptidase-IV) cleavage and renal clearance. This is close to native GHRH's half-life (~7 minutes), making sermorelin the most physiologically analogous synthetic GHRH for acute stimulation research. The short half-life means each administration produces a discrete, time-limited GH pulse rather than sustained receptor engagement.
Sermorelin has a significant clinical research advantage: it received FDA approval (as Geref) for GH deficiency diagnostics and paediatric GH deficiency treatment. This regulatory history provides published Phase 3 clinical data, pharmacokinetic characterisation, and long-term safety documentation — an unusually strong research foundation.
CJC-1295 DAC: Long-Acting GHRH Analogue
CJC-1295 with Drug Affinity Complex (DAC) is a GHRH analogue modified at lysine-29 with a C18 fatty acid chain via a maleimido-propionamido linker. This modification enables covalent binding to serum albumin, dramatically extending plasma half-life from minutes to approximately 6-8 days. Once bound to albumin, the active peptide is slowly released, maintaining sustained GHRHR stimulation.
The clinical pharmacology of CJC-1295 DAC was characterised in a Phase 2 trial by Teichman et al. (J Clin Endocrinol Metab, 2006). Single-dose administration in healthy volunteers produced dose-dependent GH and IGF-1 increases sustained over 6 days — demonstrating that once-weekly dosing could maintain elevated GH secretion throughout the inter-dose interval.
This sustained profile means CJC-1295 DAC does not produce discrete pulsatile GH patterns. Instead, it amplifies the magnitude of GH secretion across the entire dosing period — a fundamentally different GH axis exposure pattern from sermorelin's acute, pulsatile stimulation.
CJC-1295 is most commonly studied in combination with ipamorelin (a GHSR1a agonist) to address both pulse amplitude (CJC-1295) and pulse frequency (ipamorelin) simultaneously. See our CJC-1295 + Ipamorelin research guide →
Head-to-Head Comparison
| Feature | Sermorelin (GHRH 1-29) | CJC-1295 DAC |
|---|---|---|
| Sequence | GHRH 1-29 (29 aa) | GHRH analogue + DAC modification |
| Half-life | ~7-11 minutes | ~6-8 days |
| GH release pattern | Acute pulsatile | Sustained elevation |
| Regulatory history | FDA approved (Geref) | Phase 2 clinical data |
| Best suited for | Acute GH stimulation studies; pulsatile research | Sustained GH elevation; IGF-1 studies |
| Feedback preservation | Yes — short half-life preserves somatostatin feedback | Partial — sustained stimulation blunts pulsatile pattern |
| Available from EP | 5mg / 10mg | CJC+Ipam blend |
Choosing for Your Research Design
Choose sermorelin when:
Your study requires acute, time-limited GH stimulation; pulsatile GH pattern studies; or you want to leverage the existing clinical data package from FDA approval. Also preferred when somatostatin feedback preservation is important to the research design.
Choose CJC-1295 DAC when:
Your study requires sustained GH and IGF-1 elevation over days; once-weekly dosing is preferred; or you want to study the GH/IGF-1 axis effects of continuous GHRHR stimulation rather than pulsatile patterns. Often combined with ipamorelin for comprehensive GH axis research.
Frequently Asked Questions
What is the difference between CJC-1295 and sermorelin?
Does sermorelin have clinical data?
Can sermorelin and CJC-1295 be studied together?
Are CJC-1295 and sermorelin available in Australia for research?
References
- Teichman SL et al. J Clin Endocrinol Metab. 2006;91(3):799-805
- Walker RF. Growth Horm IGF Res. 2006;16(Suppl A):S13-17